These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12656811)

  • 21. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
    Figgitt DP; Noble S
    Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines.
    Kim EJ; Ramirez AL; Reeck JB; Maas CS
    Plast Reconstr Surg; 2003 Oct; 112(5 Suppl):88S-93S; discussion 94S-97S. PubMed ID: 14504489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of a vertebrate neuromuscular junction that demonstrates selective resistance to botulinum toxin.
    Coffield JA; Bakry NM; Maksymowych AB; Simpson LL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1509-16. PubMed ID: 10336546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current gaps in basic science knowledge of botulinum neurotoxin biological actions.
    Rossetto O; Pirazzini M; Montecucco C
    Toxicon; 2015 Dec; 107(Pt A):59-63. PubMed ID: 26163315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study.
    Sadick NS; Faacs
    Dermatol Surg; 2002 Sep; 28(9):817-21. PubMed ID: 12269875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum neurotoxin: A therapeutic powerhouse with broad clinical implications.
    Aldridge JHR
    JAAPA; 2023 Apr; 36(4):39-41. PubMed ID: 36976032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New neurotoxins on the horizon.
    Freeman SR; Cohen JL
    Aesthet Surg J; 2008; 28(3):325-30. PubMed ID: 19083544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin and spasticity.
    Davis EC; Barnes MP
    J Neurol Neurosurg Psychiatry; 2000 Aug; 69(2):143-7. PubMed ID: 10896682
    [No Abstract]   [Full Text] [Related]  

  • 30. Botulinum toxin decreases salivation from canine submandibular glands.
    Shaari CM; Wu BL; Biller HF; Chuang SK; Sanders I
    Otolaryngol Head Neck Surg; 1998 Apr; 118(4):452-7. PubMed ID: 9560094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology.
    Callaway JE; Arezzo JC; Grethlein AJ
    Semin Cutan Med Surg; 2001 Jun; 20(2):127-36. PubMed ID: 11474745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
    Carruthers A; Kane MA; Flynn TC; Huang P; Kim SD; Solish N; Kaeuper G
    Dermatol Surg; 2013 Mar; 39(3 Pt 2):493-509. PubMed ID: 23458294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin type B: pH change reduces injection pain, retains efficacy.
    Lowe PL; Lowe NJ
    Dermatol Surg; 2014 Dec; 40(12):1328-33. PubMed ID: 25350125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin: examining duration of effect in facial aesthetic applications.
    Flynn TC
    Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Different botulinum toxins and their specifications].
    Beylot C
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S77-85. PubMed ID: 19576490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.
    Ramirez AL; Reeck J; Maas CS
    Otolaryngol Head Neck Surg; 2002 May; 126(5):459-67. PubMed ID: 12075218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical failure of botulinum toxin A in movement disorders.
    Savica R; Grossardt BR; Bower JH; Klassen BT; Matsumoto JY
    Parkinsonism Relat Disord; 2012 Jan; 18(1):73-5. PubMed ID: 21880538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue.
    Kalandakanond S; Coffield JA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):749-55. PubMed ID: 11181902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uptake of botulinum neurotoxin into cultured neurons.
    Keller JE; Cai F; Neale EA
    Biochemistry; 2004 Jan; 43(2):526-32. PubMed ID: 14717608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.